Psoriasis is one of the most common chronic inflammatory skin diseases, affecting about 2% of the population worldwide 1 . It is defined by a thickened epidermis (acanthosis) caused by keratinocyte proliferation and massive infiltration of leukocytes into the skin. Psoriatic lesions contain larger amounts of the pro-inflammatory cytokines interleukin 17 (IL-17), IL-21, IL-22 and IL-23, which has led to the classification of psoriasis as a disease mediated by IL-17-producing helper T cells (T H 17 cells) 2 . The importance of IL-23 and IL-17 in psoriatic patients is demonstrated by the efficacy of treatment with monoclonal antibodies to IL-17 and to the cytokine receptor IL-23R 3 . Furthermore, intradermal administration of recombinant IL-23 to mice induces a psoriasiform dermatitis that mimics the human disease in histological and immunological aspects 4 .
Psoriasis is one of the most common chronic inflammatory skin diseases, affecting about 2% of the population worldwide 1 . It is defined by a thickened epidermis (acanthosis) caused by keratinocyte proliferation and massive infiltration of leukocytes into the skin. Psoriatic lesions contain larger amounts of the pro-inflammatory cytokines interleukin 17 (IL-17), IL-21, IL-22 and IL-23, which has led to the classification of psoriasis as a disease mediated by IL-17-producing helper T cells (T H 17 cells) 2 . The importance of IL-23 and IL-17 in psoriatic patients is demonstrated by the efficacy of treatment with monoclonal antibodies to IL-17 and to the cytokine receptor IL-23R 3 . Furthermore, intradermal administration of recombinant IL-23 to mice induces a psoriasiform dermatitis that mimics the human disease in histological and immunological aspects 4 .
In addition to IL-17, IL-22 also acts as a master regulator of psoriasis [5] [6] [7] . Polymorphisms in IL22 result in enhanced susceptibility to psoriasis 8 , and serum concentrations of IL-22 positively correlate with disease severity and negatively correlate with responsiveness to therapy 9 . IL-22 signaling in keratinocytes induces expression and phosphorylation of the transcription factor STAT3, which increases epidermal proliferation and de-differentiation 10 . IL-22 expression is regulated by the ligand-dependent transcription factor AhR in T H 17 cells and some populations of γδ T cells 11 and innate lymphocytes 12 . Currently described endogenous ligands for AhR also include naturally occurring dietary substances, such as L-tryptophan (L-Trp)-derived metabolites 13 . After being exposed to light, L-Trp can be metabolized to several products, including the high-affinity AhR agonist FICZ (6-formylindolo [3, 2-b] carbazole). A light-independent, H 2 O 2 -dependent pathway for the systemic generation of FICZ from L-Trp has also been described 14 . Uptake of aromatic amino acids by activated lymphoid cells is conducted mainly via the system L1 transporter, an heterodimer comprising the heavy chain CD98 (also known as SLC3A2 or 4F2) and the light chain LAT1 ('L-type amino acid transporter 1'; also known as SLC7A5). Regulation of amino acid transport through the LAT1-CD98 heterodimer is linked to T cell-activation and T cell-differentiation processes 15 .
Although T H 17 cells were once considered an important source of IL-17 and IL-22 in psoriatic skin, evidence now indicates that these cytokines are produced mainly by a population of dermal γδ T cells already identified in both humans and mice [16] [17] [18] [19] . Skin γδ T cells bear several markers of memory and effector T cells, including CD69 (ref. 20) . Lymphocytes from CD69-deficient mice show enhanced differentiation toward the T H 17 lineage 21 , and CD69-deficient mice exhibit increased severity of T H 17 cell-mediated inflammatory diseases, including collagen II-induced arthritis 22 , allergic asthma and skin contact hypersensitivity 23 , autoimmune myocarditis 24 and colitis 25 . Whether CD69 exerts an immunomodulatory effect on psoriasis by controlling IL-17 and IL-22 responses in skin γδ T cells has remained unexplored until now.
In this study we found that CD69-deficient mice developed an attenuated skin inflammatory response to the administration of IL-23, with decreased expression of IL-22 and STAT3 in the epidermis. We also found that CD69 associated with the heterodimeric aminoacid transporter LAT1-CD98 and regulated the uptake of L-Trp. This promoted the AhR-induced secretion of IL-22 by skin γδ T cells.
RESULTS

IL-23-induced psoriasiform inflammation requires CD69
To assess the role of CD69 in psoriasis, we administered consecutive intradermal injections of mouse IL-23 protein into the ears of wild-type and CD69-deficient mice. IL-23 induced more swelling, epidermal acanthosis, dermal inflammation and keratinocyte proliferation (Ki67 + nuclei) in the ears of wild-type mice than in those of CD69-deficient mice (Fig. 1a-c) . IL-23 also significantly increased the total number of CD45 + cells in wild-type mice relative to that in CD69-deficient mice (Fig. 1d) . These were mostly CD45 + CD11c − CD11b + myeloid (non-dendritic) cells, particularly Gr-1 + F4/80 − neutrophils, F4/80 lo monocytes and F4/80 hi macrophages (Fig. 1d) . Immunohistochemistry also revealed more Ly6G + neutrophils and F4/80 + monocytes and macrophages in wild-type mice than in CD69-deficient mice after treatment with IL-23 ( Fig. 1c) These results indicated that the absence of CD69 prevented the development of psoriasis after intradermal injection of IL-23.
Reduced expression of IL-22 and STAT3 in CD69 deficiency
We next determined whether CD69 controls the expression of inflammatory mediators in the skin. IL-23 induced higher expression of Cxcl1, S100a8 and S100a9 mRNA in wild-type mice than in CD69-deficient mice, while both genotypes showed a similar increase in Ccl20 mRNA (Fig. 2a) . IL-23 treatment increased the expression of Il6, Tnf, Il1b and IL-17 mRNA to a similar extent in wild-type mice and CD69-deficient mice, while the expression of Tgfb mRNA in the skin was not altered (Fig. 2b,c) . In contrast, IL-23 induced a very modest increase in IL-22 expression in the skin of CD69-deficient relative to that in the skin of wild-type mice (Fig. 2d) . Neither genotype showed detectable expression of IL-22 or IL-17 in CD4 + T cells obtained from the ear-draining lymph nodes of mice given injection of IL-23, followed by re-stimulation of the cells in vitro (data not shown). These results indicated that the weak cutaneous inflammatory response to IL-23 injection observed in the CD69-deficient mice might have been related to attenuated skin production of IL-22. Expression of the cytokine receptor IL-22R in skin is restricted to non-hematopoietic cells, such as keratinocytes and fibroblasts. In these cells, the binding of IL-22 to IL-22R activates STAT3 (ref. 26 ). Injections of IL-23 into the ear caused a uniform increase in epidermal STAT3 expression and phosphorylation (at Ser727 and Tyr705) in wild-type mice, compared with only patchy induction of these parameters in CD69-deficient mice (Fig. 2e,f) . This indicated that CD69 controlled the expression of IL-22 and STAT3.
Enhancement of the expression of AhR and IL-22 by CD69 CD69 is a negative regulator of the secretion of IL-17 by T H 17 cells 27 , but its effect on IL-22 secretion is not known. This is a crucial question, since IL-22 is produced by T H 17 lymphocytes 13 . Naive CD4 + T cells from CD69-deficient mice polarized for 48 h in vitro into T H 17 cells secreted less IL-22 than did their wild-type counterparts (Supplementary Fig. 1a) . Moreover, flow cytometry after intracellular staining showed that CD69-deficient T H 17 cells had lower expression of AhR than that of wild type T H 17 cells (Supplementary Fig. 1b) . We found that expression of mRNA from the AhR target genes Il22, Ahr, Ahrr, Cyp1a and Cyp1b was impaired in CD69-deficient T H 17 cells relative to that in wild-type T H 17 cells (Supplementary Fig. 1c) .
In IL-23-driven psoriasis, IL-22 and IL-17 are secreted by dermal γδ T cells 16, 18 . To characterize the resident T cell populations in the skin of both wild-type mice and CD69-deficient mice, we analyzed total skin-cell suspensions and separated dermal and epidermal layers by flow cytometry. These experiments indicated that CD3 hi cells were dendritic epidermal γδ T cells, while 50-80% of dermal CD3 lo cells were γδ T cells (Supplementary Fig. 1d ). Both CD3 hi γδ T cell populations and CD3 lo γδ T cell populations in untreated skin had high expression of CD69 (Supplementary Fig. 1e ). Although CD69 expression is linked to the generation and migration of skin-resident memory T cells 28 , the frequency of skin-resident epidermal (CD3 hi ) and dermal (CD3 lo ) γδ T cell populations was similar in wild-type mice and CD69-deficient mice (Supplementary Fig. 1f ). 
A r t i c l e s
Simultaneous intradermal injection of IL-23 (into the ears) and systemic (intraperitoneal) administration of the secretion inhibitor brefeldin A to wild-type mice promoted the accumulation of IL-22 in dermal CD3 lo γδ T cells (Supplementary Fig. 2a) . Moreover, flow cytometry of dermal γδ T cells sorted from wild-type mice and stimulated in vitro with IL-23 plus IL-1β revealed an acute peak of IL-22 (maximal at 24 h after stimulation) and higher AhR expression than that of unstimulated cells (Supplementary Fig. 2b) . However, the secretion of IL-17 from sorted dermal γδ T cells was sustained for up to 72 h after stimulation (Supplementary Fig. 2b) .
Sorted CD69-deficient dermal γδ T cells released less IL-22 than did wild-type dermal γδ T cells when stimulated with IL-23 and IL-1β in vitro, whereas their IL-17 production was similar (Fig. 3a) . Moreover, the expression of AhR induced by IL-23 and IL-1β in vitro stimulation was lower in CD69-deficient dermal γδ T cells than in wild-type dermal γδ T cells (Fig. 3b) .
To parse the function of CD69 in IL-22 secretion by dermal γδ T cells in vivo, we prepared skin-cell suspensions 12 h after the administration of a single dose of IL-23 into the ears of wild-type and CD69-deficient mice, followed by stimulation of the cell suspensions with the phorbol ester PMA and ionomycin. Flow cytometry showed lower IL-22 expression in CD69-deficient dermal γδ T cells than in wild-type dermal γδ T cells (Fig. 3c) . Simultaneous intradermal injection of IL-23 and intraperitoneal administration of brefeldin A resulted in lower expression of IL-22 in dermal γδ T cells from CD69-deficient mice than in those from wild-type mice (Fig. 3d) .
We observed a similar expression of the transcription factor RORγt in dermal γδ T cells from CD69-deficient and those from wild-type mice ( Supplementary Fig. 2c ). Likewise, phosphorylation of STAT3 and STAT5 following stimulation with IL-23 plus IL-1β was similar in CD69-deficient dermal γδ T cells and wild-type dermal γδ T cells (Supplementary Fig. 2c ). Flow cytometry of skin suspensions from mice with sequence encoding green fluorescent protein (GFP) reporter knocked into the gene encoding IL-23R 29 showed that dermal γδ T cells (CD3 lo ) were the main population among IL-23R + (GFP + ) cells in the skin at steady state, while epidermal γδ T cells (CD3 hi ) were IL-23R − (GFP − ) (Supplementary Fig. 2d ). Staining of IL-23R showed that the number of IL-23R + dermal γδ T cells and their molecular density of IL-23R were similar for CD69-deficient mice and wild-type mice (Supplementary Fig. 2e ). A r t i c l e s CD69 is known to modulate the trafficking of effector T cells 30 . To investigate whether CD69-mediated egress of lymphocytes from the lymph node was involved in the IL-23 skin-inflammation model, we transferred wild-type (CD45.1 + ) whole bone marrow cells intravenously into lethally γ-irradiated CD69-deficient or wild-type (CD45.2 + ) host mice (Fig. 3e) . After 2 months of reconstitution, we administered IL-23 intradermally to the mice. CD69-deficient host mice displayed less skin inflammation than that of wild-type host mice (Fig. 3e) . Flow cytometry of skin-cell suspensions showed a similar increase in host-derived (CD45.2 + ) dermal γδ T cells in CD69-deficient mice and wildtype host mice after treatment with IL-23 (Fig. 3f) . We observed significantly more infiltrating CD11b + myeloid cells and Ly6G + Ly6C + neutrophils of donor (CD45.1 + ) origin in the skin of wild-type mice than in that of CD69-deficient mice (Fig. 3g) . Because skin-resident dermal γδ T cells are radioresistant and proliferate in situ 20 , they persisted in the bone-marrow-chimeric hosts, which would account for the differences between the wild-type hosts and CD69-deficient hosts. These observations ruled out the possibility of a role for the migration of CD69 + T lymphocytes from the lymph nodes as a triggering mechanism.
IL-22-and AhR-mediated skin inflammation downstream of CD69
To address whether the attenuated skin inflammation observed in CD69-deficient mice was due to reduced secretion of IL-22 from the skin, we simultaneously injected IL-22 and IL-23 intradermally into wild-type mice and CD69-deficient mice. We observed a similar degree of ear swelling in mice of each genotype (Fig. 4a) , as well as substantial acanthosis (Fig. 4b) and similar infiltration of myeloid cells into the skin (Fig. 4c) , proliferation of dermal γδ T cells (Fig. 4d,e) , and expression of Il1b and IL-22-related genes, such S100a7, S100a8 and S100a9, in mice of each genotype (Fig. 4f) . Moreover, intradermal injection of IL-22 alone induced (f) Quantitative PCR analysis of Il1b, S100a7, S100a8 and S100a9 mRNA in the skin of mice as in a (presented as in Fig. 2a,b) . P values A r t i c l e s similar ear swelling and expression of Il1b, S100a8 and S100a9 in CD69-deficient skin and wild-type skin (Supplementary Fig. 3a ). These observations suggested that the effect of IL-22 in the context of IL-23-induced skin inflammation was independent of CD69 expression. Direct involvement of AhR in the secretion of IL-22 by dermal γδ T cells was addressed by simultaneous administration of three intradermal injections of IL-23 into the ears of AhR-deficient and wildtype mice, as well as intraperitoneal administration of brefeldin A. Flow cytometry of skin-cell suspensions showed fewer IL-22 + dermal γδ T cells in AhRdeficient mice than in wild-type mice, while the number of IL-17 + γδ T cells was increased similarly in the skin of each genotype (Supplementary Fig. 3b ). In addition, we stimulated sorted CD69-deficient and wild-type dermal γδ T cells in vitro with IL-23 plus IL-1β in the presence of the AhR inhibitor CH-223191, which prevented secretion of IL-22 by cells of each genotype (Supplementary Fig. 3c ). To assess whether IL-22 secretion depended on CD69 in γδ T subsets in locations other than the skin, we studied splenic CD27 − γδ T cells, which secrete IL-17 and IL-22 after being stimulated with IL-23 (ref. 31 ). These cells expressed CD69 after being stimulated with IL-23 and/or IL-1β ( Supplementary  Fig. 3d) . Splenic CD27 − γδ T cells from CD69-deficient mice had lower expression of IL-22 than that of their wild-type counterparts, and this was abrogated by CH-223191 (Supplementary Fig. 3e ).
These observations indicated that activation of AhR was required for CD69 to regulate the IL-23-induced IL-22 expression.
To address whether inhibition of AhR controlled IL-23-dependent skin inflammation, we injected IL-23 intradermally into wild-type and CD69-deficient mice, together with daily intraperitoneal administration of CH-223191. This treatment decreased inflammation in wild-type mice but had a very modest effect on CD69-deficient mice (Fig. 5a,b) . Systemic administration of CH-223191 also reduced the number of IL-23-driven Ly6G + Ly6C + neutrophils in wild-type skin to numbers similar to those in CD69-deficient skin (Fig. 5c) . Also, the expression of Il22 mRNA and of the IL-22 target genes S100a9 and S100a7 in whole skin was significantly lower in wild-type mice that received CH-223191 plus IL-23 than in wild-type mice that received IL-23 alone and was similar to that in CD69-deficient mice treated with IL-23 (Fig. 5d) . These results indicated that AhR and IL-22 contributed to skin inflammation controlled by CD69. 
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A r t i c l e s
CD69 associates with LAT1-CD98 and controls amino acid uptake To address the mechanism by which CD69 regulated the AhRmediated expression of IL-22, we used mass spectrometry to explore possible interactions of CD69 with regulators of AhR. We found that CD69 associated with several nutrient transporters, including CD98, LAT1, MOT1 and GTR1 (Supplementary Table 1 and Supplementary Fig. 4a) . The LAT1-CD98 complex is a major intake receptor for aromatic amino acids such as L-Trp, which is a source of ligands for AHR 14 . Immunoprecipitation experiments showed that CD69 associated with both chains of the LAT1-CD98 transporter in human Jurkat T cells activated with PMA and ionomycin (Fig. 6a) . 
Confocal imaging and a proximity-ligation assay also indicated an
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A r t i c l e s association of CD69 with CD98 and LAT1 on the plasma membrane of activated Jurkat T cells (Fig. 6b,c) . Activated CD4 + T cells from CD69-deficient mice had lower surface expression of LAT1 but not lower total expression of LAT1 than that of their wild-type counterparts, while plasma-membrane expression and global expression of CD98 were similar in cells of each genotype (Fig. 6d) . Membrane expression of LAT1 was also significantly higher in sorted wild-type dermal γδ T cells than in their CD69-deficient counterparts (Fig. 6e) . After stimulation with antibody to the invariant signaling protein CD3 (anti-CD3), wildtype CD4 + T cells and CD69-deficient CD4 + T cells showed a similar increase in Slc7a5 mRNA (which encodes LAT1) and Slc3a2 mRNA (which encodes CD98) ( Supplementary Fig. 4b) ; this suggested that CD69 might have been regulating LAT1 dynamics and/or its stability at the membrane. Moreover, no significant difference between activated CD4 + T cells from CD69-deficient and those from wild-type mice was observed in the expression of mRNA encoding other amino acid transporters, except for higher expression of Slc38a2 mRNA (which encodes the transporter SNAT2), regulated by amino-acid starvation 32 , in CD69-deficient CD4 + T cells than in their wild-type counterparts (Supplementary Fig. 4c) .
Assays of the uptake of 3 H-labeled L-Trp, L-Phe and L-Leu showed that CD69-deficient γδ T cells isolated from spleen and lymph nodes had slower uptake of L-Trp via LAT1 than that of their wild-type counterparts (Fig. 6f,g ). Likewise, less uptake of amino acids via LAT1 was detected in CD69-deficient CD4 + T cells than in wild-type CD4 + T cells (Supplementary Fig. 5a ). Incubation with an antibody that promotes CD69 internalization 23 also triggered the internalization of LAT1 in CD4 + T cells but had no effect on surface expression of CD98 (Supplementary Fig. 5b ). HEK-293 human embryonic kidney cells were co-transfected with plasmids encoding CD69-GFP and LAT1-Cherry fusion proteins and then incubated with labeled anti-CD69; this showed co-internalization of CD69 and LAT1 (Supplementary Fig. 5c ). Moreover, antibody-induced internalization of CD69 impaired the uptake of L-Trp and L-Phe in CD4 + wild-type T cells relative to their uptake after treatment with control antibody, but it had no effect on amino acid uptake in CD69-deficient cells ( Supplementary  Fig. 5d ). These observations indicated that CD69 was associated with LAT1 and regulated its localization at the plasma membrane and amino acid transport.
Mass-spectrometry analysis showed less intracellular accumulation of FICZ (a metabolic and photoxidative product of L-Trp that activates AhR) in Jurkat T cells cultured in L-Trp-enriched medium treated with the LAT1 inhibitor BCH than in cells not treated with BCH (Fig. 6h) . Moreover, through use of the intrinsic fluorescence of FICZ, we observed enhanced intracellular transport of FICZ into T cells at 37 °C but not at 4 °C (Fig. 6i) . Uptake of FICZ from the extracellular medium was lower in CD69-deficient T cells than in wild-type T cells, and these differences were abrogated by the LAT1 inhibitor (Fig. 6i) . These results demonstrated that LAT1-CD98 facilitated the intracellular transport of FICZ in a CD69-regulated manner.
CD69-LAT1-CD98 regulate mTORC and AhR-mediated IL-22 expression
The LAT1-mediated transport of amino acids is required for activation of the metabolic-checkpoint-kinase complex mTORC pathway 33 . CD69-deficient and wild-type naive CD4 + T cells were polarized toward T H 17 cells in vitro and mTORC signaling was assessed as phosphorylation of the kinases mTORC1, S6 and 4E-BP1 (at 24-96 h). CD69 expression was dispensable for early activation of mTORC at 24 h after engagement of the T cell antigen receptor (TCR) (Supplementary Fig. 6a) . However, the maintenance of mTORC signaling is influenced by amino acid uptake 33 . T H 17 cells from CD69-deficient mice showed impaired phosphorylation of S6 and 4E-BP1 after 96 h relative to that of their wild-type counterparts (Supplementary Fig. 6b) .
We next addressed the role of LAT1-CD98-mediated transport of aromatic amino acids in AhR-dependent responses. Addition of the LAT1 inhibitor BCH abrogated IL-22 production in CD69-deficient and wild-type T H 17 cells (Supplementary Fig. 6c) . In contrast, addition of the AhR ligand FICZ induced the secretion of IL-22 from cells of each genotype (Supplementary Fig. 6c) . Culture of T H 17 cells with L-Trp-enriched Iscove's modified Dulbecco's medium (IMDM) 13 restored the secretion of IL-22 from CD69-deficient T H 17 to the secretion of IL-22 by wild-type cells (Supplementary Fig. 6c) . Moreover, in the presence of LAT1 inhibitor BCH, the IL-22 expression in dermal γδ T cells stimulated in vitro with IL-23 plus IL-1β was reduced in wild-type cells to an amount similar to that observed in their CD69-deficient counterparts (Fig. 7a) . Conversely, culture in IMDM or the addition of FICZ induced similar IL-22 expression in CD69-deficient dermal γδ T cells and wild-type dermal γδ T cells (Fig. 7a) . Supplementation of RPMI medium with L-Trp also increased the release of IL-22 from CD69-deficient and wild-type CD4 + T H 17 cells (Fig. 7b) , although differences in IL-17 secretion remained (Fig. 7b) . Expression of the AhR-regulated genes Ahrr and Il22 was higher in CD69-deficient and wild-type CD4 + naive cells polarized in vitro into the T H 17 subset and cultured in RPMI medium supplemented with L-Trp or IMDM than in cells activated with anti-CD3 and antibody to the costimulatory receptor CD28 (anti-CD28) (the 'T H 0-polarizing' condition) (Fig. 7c) . The addition of BCH decreased the expression of Ahrr and Il22 mRNA in CD69-deficient and wild-type cells (Fig. 7c) .
Psoriatic skin displays increased expression of the tryptophandegrading enzymes IDO (indoleamine 2,3-dyoxigenase) and TDO (tryptophan 2,3-dioxygenase), which catalyze the first step in L-Trp catabolism by the kynurenine pathway, and higher expression of the enzyme L-kynureninase, which further degrades kynurenine 34 . Thus, we assessed their expression in whole skin after intradermal injection of IL-23 alone or IL-23 plus IL-22. The expression of mRNA encoding IDO or L-kynureninase was induced similarly in CD69-deficient skin and wild-type skin, while the expression of mRNA encoding TDO was not induced by IL-23 ( Supplementary Fig. 6d) .
To determine whether uptake of L-Trp in vivo by dermal γδ T cells modulated psoriasis in CD69-deficient and wild-type mice, we administered L-Trp daily (intraperitoneally) simultaneously with intradermal injection of IL-23. The administration of L-Trp resulted in similar skin swelling in CD69-deficient mice and wild-type mice (Fig. 7d) and similar numbers of infiltrating CD45 + CD11b + F4/80 + macrophages and CD45 + CD11b + F4/80-Ly6G + Ly6C + neutrophils in the skin of CD69-deficient mice and that of wild-type mice (Fig. 7e,f) . We also observed similar numbers of IL-22 + dermal γδ T cells in CD69-deficient mice and wild-type mice following the administration of L-Trp (Fig. 7g) . Hence, these results indicated that CD69 regulated the surface expression of LAT1, the uptake of L-Trp, an intracellular increase in FICZ, and subsequent AhR activation and IL-22 secretion in dermal γδ T cells (Supplementary Fig. 7 ).
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A r t i c l e s
Upregulation of CD69, LAT1 and IL-22 in psoriasis We next assessed whether CD69 + γδ T cells were present in skin samples from patients with moderate to severe psoriasis. CD69 expression was detected by immunofluorescence in V γ 9 + T cells in psoriatic skin lesions (Fig. 8a) . The frequency of V γ 9 + CD69 + T cells positively correlated with the psoriasis area severity index (Fig. 8b) . Immunofluorescence staining showed that IL-22-secreting V γ 9 + T cells in the dermal layer expressed CD69 (Fig. 8c) . In agreement with that, expression of IL22 and TNF mRNA was higher in psoriatic skin than in biopsies of healthy skin (Fig. 8d) .
The frequency of circulating CD69 + CLA + V γ 9 + T cells was greater in psoriatic patients than in healthy control subjects (Fig. 8e) . To assess the ability of these cells to produce IL-22, we stimulated circulating γδ T cells from psoriatic patients in vitro with a cytokine 'cocktail' (IL-23 plus IL-1β plus IL-6 plus TGF-β). IL-22 expression in human V γ 9 + γδ T cells was decreased by the addition of inhibitors of AhR or LAT1 (Fig. 8f,g ). Quantitative RT-PCR analysis of mRNA from wholeskin biopsies showed significantly higher expression of SLC7A5 and CD69 mRNA in psoriatic lesions than in unaffected regions, whereas SLC3A2 mRNA was not expressed differentially in these regions (Fig. 8h) . These results demonstrated LAT1-mediated regulation of AhR and IL-22 in γδ T cells from patients with psoriasis.
DISCUSSION
The pathogenesis of psoriasis involves cross-talk between skinresident innate immune cells and keratinocytes, which is orchestrated by cytokines such as 35) . Here we found that CD69 associated with the transporter complex LAT1-CD98 and enhanced the uptake of L-Trp, a metabolic precursor of AhR ligands that promoted IL-22 secretion 13, 14 . The transcriptional activity of STAT3 induced by IL-22 in keratinocytes upregulates the expression of pro-inflammatory molecules such as keratin 17, S100A7, S100A8 and S100A9, as well as several CXCL chemokines 6, 36 . Fig. 2a,b) . A r t i c l e s IL-22 also induces keratinocyte proliferation through the PI3K-Akt-mTORC signaling pathway 37 . The deficient expression of IL-22 and activation of STAT3 in the skin of CD69-deficient mice we found here provides a mechanistic link that explains the attenuated dermal inflammation and keratinocyte proliferation observed after administration of IL-23. γδ TCR-deficient mice display attenuated psoriatic plaque formation in response to IL-23 (ref. 16 ) and imiquimod 18 . The role of CD69 as an enhancer of AhR activity and IL-22 release in γδ T cells in vitro and in vivo correlates well with clinical data showing increased CD69 expression on V γ 9 + T cells from the skin and the bloodstream of psoriatic patients.
CD69 associated with the amino-acid transporter complex LAT1-CD98 on the plasma membrane of activated T cells and controlled the activation of mTORC. Further studies are needed to ascertain whether CD69 regulates other targets of mTORC, such as the autophagy route 38 and HIF-1α through AhR 39 . Different regions of CD98 control the uptake of amino acids and β 1 -integrin-mediated cell proliferation 40 . However, published studies have shown no difference in the proliferation rate of CD69-deficient T lymphocytes and that of wild-type T lymphocytes 41 , which suggests that the association of CD69 with the LAT1-CD98 complex in activated immune cells modulates the uptake of amino acids specifically.
Cytoplasmic L-Trp acts as a chromophore that is converted by exposure to light into active AhR ligands, including FICZ 13 . The characterization of a light-independent metabolic route for the generation of FICZ from the intracellular pool of L-Trp 14 suggests that regulation of entry of the precursor might determine the amount of cellular FICZ and AhR activation. Our results demonstrated that LAT1-CD98 regulated the intracellular accumulation of FICZ.
Inhibition of AhR protects against inflammation induced by IL-23 without substantial alteration of the keratinocyte layers. However, depletion of AhR in keratinocytes disrupts epidermal homeostasis, which enhances psoriasis in response to imiquimod, although lower expression of IL-22 in the skin of fully AhR-deficient mice than in the skin of wild-type mice has been detected 42 . Differences between the IL-23-induced psoriasis model and imiquimod-induced psoriasis model exist 2 . Toll-like-receptor-7-independent epidermal hyperproliferative responses induced by keratinocyte damage are involved in the induction of psoriasis in the imiquimod model 18, 43 . Fig. 2a,b) , and correlation analysis of CD69 and SLC7A5 (bottom right: r = 0.34; P = 0.02). Each symbol (b,d,e,h) represents an individual donor; small horizontal lines indicate the mean (± s.d.). *P < 0.05 and **P < 0.001 (unpaired t-test). Data are representative of experiments with ten patients (a-c) ten patients and nine healthy subjects (d), nine patients and six healthy subjects (e; mean + s.e.m.), three patients (f), three patients and six healthy subjects (pooled) (g; mean + s.e.m.) or fifteen patients (h).
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AhR controls the terminal differentiation of epidermal cells and the expression of genes encoding proteins linked to skin barrier function, such as filaggrin 44, 45 . Hence, AhR in keratinocytes is required for skin homeostasis, but its activation in inflammatory cells mediates inflammation. CD69 did not affect the secretion of IL-17 by innate γδ T cells, in contrast to its effect on CD4 + T H 17 T cells 27 . The greater secretion of IL-17 by CD69-deficient CD4 + T H 17 cells than by wildtype CD4 + T H 17 cells is due to increased phosphorylation of STAT3 and increased RORγt expression 27 . This was not observed in dermal γδ T cells, owing to the fact that the transcription factors that control the T H 17 differentiation CD4 + T cells, such as STAT3, are not required for the development of IL-17 + (RORγt + ) γδ T cells that originated in fetal thymus 46, 47 .
Prevention of the uptake of L-Trp via LAT1 abrogated the AhRdependent secretion of IL-22 from human peripheral γδ T cells from psoriatic patients, which would suggest a possible role for the uptake of dietary L-Trp in psoriasis. Notably, in vivo administration of L-Trp increased the severity of inflammatory responses elicited by IL-23 independently of CD69 expression. Overall, these data indicate that L-Trp catabolism has an important role in the pathophysiology of psoriasis, not only due to the regulation of kynurenine but also by its effect on other metabolites that might contribute to skin inflammation. In conclusion, our study has established a biological role for CD69 in the control of amino acid uptake and the regulation of AhR activation and IL-22 expression in γδ and T H 17 cells and indicates that CD69 contributes to the development of psoriasis.
METHODS
Methods and any associated references are available in the online version of the paper. 
